AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 12653876 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent VLCD (2 weeks every third month after initial 16 weeks)
Number of subjects: 334
Study 12653876 — intervention group
Group type: EXPERIMENTAL
Intervention: On-demand VLCD (as needed when body weight passed an individualized cut-off)
Number of subjects: 334
Study 12653876 — intervention group
Group type: EXPERIMENTAL
Intervention: On-demand VLCD (for male completers)
Number of subjects: 334
Study 12653876 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent VLCD (for male completers)
Number of subjects: 334
Study 12653876 — intervention group
Group type: COMPARATOR
Intervention: Both groups (overall cardiovascular risk factors)
Number of subjects: 334
Study 12653876 — intervention group
Group type: COMPARATOR
Intervention: Both groups (anthropometric measures, insulin, HDL- and LDL-cholesterol)
Number of subjects: 334
Study 10732887 — intervention group
Group type: EXPERIMENTAL
Intervention: PTCA
Number of subjects: 1018
Study 10732887 — intervention group
Group type: COMPARATOR
Intervention: Medical Treatment
Number of subjects: 1018
Study 10732887 — intervention group
Group type: COMPARATOR
Intervention: Both Groups
Number of subjects: 1018
Study 9026268 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 alpha-hydroxy vitamin D3 (0.75 micrograms/day)
Number of subjects: 113
Study 9026268 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 113
Study 1395074 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril (20 mg)
Number of subjects: 16
Study 1395074 — intervention group
Group type: COMPARATOR
Intervention: Cadralazine
Number of subjects: 16
Study 1395074 — intervention group
Group type: COMPARATOR
Intervention: Nitrendipine
Number of subjects: 16
Study 3903572 — intervention group
Group type: EXPERIMENTAL
Intervention: Terbutaline (1 mg) administered from pressurised aerosol through a nebuhaler
Number of subjects: 20
Study 3903572 — intervention group
Group type: COMPARATOR
Intervention: Terbutaline (4 mg) as nebulised solution
Number of subjects: 20
Study 31442335 — intervention group
Group type: EXPERIMENTAL
Intervention: Terbutaline (8 x 0.5 mg daily)
Number of subjects: 46
Study 31442335 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study 30598484 — intervention group
Group type: EXPERIMENTAL
Intervention: iCT‐R (internet-delivered cognitive training for resilience)
Number of subjects: 570
Study 30598484 — intervention group
Group type: COMPARATOR
Intervention: Supported online training of an alternative intervention
Number of subjects: 570
Study 30598484 — intervention group
Group type: COMPARATOR
Intervention: Training-as-usual
Number of subjects: 570
Study 27025829 — intervention group
Group type: EXPERIMENTAL
Intervention: Clindamycin 300 mg 4 times daily for 7 days
Number of subjects: 401
Study 27025829 — intervention group
Group type: COMPARATOR
Intervention: TMP-SMX 320 mg/1600 mg twice daily for 7 days
Number of subjects: 401
Study 27025829 — intervention group
Group type: EXPERIMENTAL
Intervention: Clindamycin
Number of subjects: 401
Study 27025829 — intervention group
Group type: COMPARATOR
Intervention: TMP-SMX
Number of subjects: 401
Study 24942540 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous tocilizumab (TCZ‐SC) 162 mg every other week
Number of subjects: 656
Study 24942540 — intervention group
Group type: COMPARATOR
Intervention: Subcutaneous placebo (PBO‐SC) every other week
Number of subjects: 656
Study 22389077 — intervention group
Group type: EXPERIMENTAL
Intervention: d‐methamphetamine (0.42 mg/kg)
Number of subjects: 20
Study 22389077 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 20579835 — intervention group
Group type: EXPERIMENTAL
Intervention: 24-hour recall period using MD Anderson Symptom Inventory (MDASI)
Number of subjects: 42
Study 20579835 — intervention group
Group type: EXPERIMENTAL
Intervention: Seven-day recall period using MD Anderson Symptom Inventory (MDASI)
Number of subjects: 42
Study 20579835 — intervention group
Group type: COMPARATOR
Intervention: Both recall periods (24-hour and seven-day)
Number of subjects: 42
Study 20579835 — intervention group
Group type: EXPERIMENTAL
Intervention: Seven-day recall period (patient preference)
Number of subjects: 42
Study 17852683 — intervention group
Group type: EXPERIMENTAL
Intervention: Short work:rest exercise protocol (6:9 s)
Number of subjects: 9
Study 17852683 — intervention group
Group type: EXPERIMENTAL
Intervention: Long work:rest exercise protocol (24:36 s)
Number of subjects: 9
Study 17852683 — intervention group
Group type: COMPARATOR
Intervention: Both short and long exercise protocols
Number of subjects: 9
Study 15223092 — intervention group
Group type: EXPERIMENTAL
Intervention: Active cue-exposure procedure with immediate feedback about physiological arousal after exposure to cocaine-related stimuli
Number of subjects: 81
Study 15223092 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 81
Study 11136839 — intervention group
Group type: EXPERIMENTAL
Intervention: G-CSF (5 microg/kg per day)
Number of subjects: 210
Study 11136839 — intervention group
Group type: COMPARATOR
Intervention: Control (antibiotics ceftazidime and amikacin without G-CSF)
Number of subjects: 210
Study 9847275 — intervention group
Group type: EXPERIMENTAL
Intervention: Tidal volume (VT) below 10 ml/kg of body weight
Number of subjects: 116
Study 9847275 — intervention group
Group type: COMPARATOR
Intervention: Conventional ventilatory approach with VT at 10 ml/kg or above
Number of subjects: 116
Study 9847275 — intervention group
Group type: EXPERIMENTAL
Intervention: Tidal volume reduction strategy
Number of subjects: 116
Study 8026282 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet plus twice daily insulin
Number of subjects: 303
Study 8026282 — intervention group
Group type: COMPARATOR
Intervention: Diet therapy
Number of subjects: 303
Study 2511683 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged low-dose intravenous nitroglycerin
Number of subjects: 0
Study 53654 — intervention group
Group type: EXPERIMENTAL
Intervention: Single and multiple agent chemotherapy
Number of subjects: 188
Study 53654 — intervention group
Group type: COMPARATOR
Intervention: No immediate treatment
Number of subjects: 188
Study 31150799 — intervention group
Group type: EXPERIMENTAL
Intervention: Statin treatment prescribed after baseline visit
Number of subjects: 900
Study 31150799 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral fat tolerance test (OFTT) meal ingestion
Number of subjects: 900
Study 31150799 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up visits for plasma TG measurements
Number of subjects: 900
Study 30177026 — intervention group
Group type: EXPERIMENTAL
Intervention: Artichoke leaf extract (ALE) 1800 mg/d (four tablets) for 12 weeks
Number of subjects: 80
Study 30177026 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 27304659 — intervention group
Group type: EXPERIMENTAL
Intervention: Active management
Number of subjects: 654
Study 27304659 — intervention group
Group type: COMPARATOR
Intervention: Expectant management
Number of subjects: 654
Study 25424924 — intervention group
Group type: EXPERIMENTAL
Intervention: RTS,S/AS01
Number of subjects: 36
Study 25424924 — intervention group
Group type: EXPERIMENTAL
Intervention: RTS,S/AS02
Number of subjects: 36
Study 25424924 — intervention group
Group type: COMPARATOR
Intervention: RTS,S/saline
Number of subjects: 36
Study 25424924 — intervention group
Group type: EXPERIMENTAL
Intervention: RTS,S/AS01 and RTS,S/AS02
Number of subjects: 36
Study 25424924 — intervention group
Group type: COMPARATOR
Intervention: RTS,S/AS and RTS,S/saline
Number of subjects: 36
Study 23163141 — intervention group
Group type: EXPERIMENTAL
Intervention: SQNYPBF (Shenmai Injection and Sulfotanshinone Sodium Injection, intravenously dripped once daily for 7 days)
Number of subjects: 85
Study 23163141 — intervention group
Group type: COMPARATOR
Intervention: Control group (routine therapies including anti-infection, nutrition support, and glucose control with insulin pump)
Number of subjects: 85
Study 21209497 — intervention group
Group type: EXPERIMENTAL
Intervention: rtACS (repetitive transorbital alternating current stimulation) for 12 days
Number of subjects: 98
Study 21209497 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined drug therapy/rtACS (D/ACS)
Number of subjects: 98
Study 21209497 — intervention group
Group type: COMPARATOR
Intervention: Control group D (conventional drug therapy)
Number of subjects: 98
Study 21209497 — intervention group
Group type: EXPERIMENTAL
Intervention: rtACS (ACS)
Number of subjects: 98
Study 16675000 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin 300 mg/day for 2 weeks
Number of subjects: 28
Study 15583361 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard care plus home visits from a nurse, consultation with an exercise specialist and/or nutritionist
Number of subjects: 40
Study 15583361 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 40
Study 12021952 — intervention group
Group type: EXPERIMENTAL
Intervention: Riluzole 50 mg b.i.d.
Number of subjects: 168
Study 12021952 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 168
Study 10743482 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified milk fat (M)
Number of subjects: 18
Study 10743482 — intervention group
Group type: COMPARATOR
Intervention: Conventional milk fat (D)
Number of subjects: 18
Study 7720850 — intervention group
Group type: EXPERIMENTAL
Intervention: Acculturation and age
Number of subjects: 691
Study 7720850 — intervention group
Group type: EXPERIMENTAL
Intervention: Having a primary sexual partner
Number of subjects: 691
Study 7720850 — intervention group
Group type: EXPERIMENTAL
Intervention: Having more than one sexual partner in the last month
Number of subjects: 691
Study 7720850 — intervention group
Group type: EXPERIMENTAL
Intervention: Perception of being at high STD risk
Number of subjects: 691
Study 7720850 — intervention group
Group type: EXPERIMENTAL
Intervention: Attitude about condoms
Number of subjects: 691
Study 7720850 — intervention group
Group type: EXPERIMENTAL
Intervention: History of having an STD
Number of subjects: 691
Study 1789348 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychoelectrostimulation
Number of subjects: 76
Study 1789348 — intervention group
Group type: COMPARATOR
Intervention: Hormonal therapy
Number of subjects: 76
Study 6113353 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous acyclovir (7-day course)
Number of subjects: 10
Study 6113353 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 30031018 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic magnetic sphincter augmentation (MSA)
Number of subjects: 152
Study 30031018 — intervention group
Group type: COMPARATOR
Intervention: Double-dose proton pump inhibitors (BID PPI)
Number of subjects: 152
Study 28424223 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose DCB (2-µg/mm2 surface dose of paclitaxel)
Number of subjects: 294
Study 28424223 — intervention group
Group type: COMPARATOR
Intervention: Uncoated PTA balloon
Number of subjects: 294
Study 28424223 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose DCB
Number of subjects: 294
Study 25827407 — intervention group
Group type: EXPERIMENTAL
Intervention: Silver containing garment (3.6% w/w) worn for 8 hours during 5 consecutive days
Number of subjects: 30
Study 24650952 — intervention group
Group type: EXPERIMENTAL
Intervention: Lixisenatide 20 μg once-daily for 24 weeks
Number of subjects: 0
Study 24650952 — intervention group
Group type: EXPERIMENTAL
Intervention: Lixisenatide 20 μg once-daily
Number of subjects: 0
Study 24650952 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 22183208 — intervention group
Group type: EXPERIMENTAL
Intervention: 12‐week standard exercise program (moderate‐intensity to high‐intensity activity 3 or more days per week)
Number of subjects: 855
Study 22183208 — intervention group
Group type: COMPARATOR
Intervention: Standard antenatal care (control group)
Number of subjects: 855
Study 22183208 — intervention group
Group type: EXPERIMENTAL
Intervention: 12‐week standard exercise program
Number of subjects: 855
Study 19793585 — intervention group
Group type: EXPERIMENTAL
Intervention: Cocoa butter cream
Number of subjects: 300
Study 19793585 — intervention group
Group type: COMPARATOR
Intervention: Placebo cream
Number of subjects: 300
Study 17686445 — intervention group
Group type: EXPERIMENTAL
Intervention: Gefitinib and Erlotinib
Number of subjects: 0
Study 17686445 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin/Gemcitabine therapy
Number of subjects: 0
Study 17686445 — intervention group
Group type: EXPERIMENTAL
Intervention: XRCC3 240 Met/Met mutation
Number of subjects: 0
Study 15848611 — intervention group
Group type: EXPERIMENTAL
Intervention: CsA treatment with FF genotype
Number of subjects: 67
Study 15848611 — intervention group
Group type: EXPERIMENTAL
Intervention: CsA and Tac treatment
Number of subjects: 67
Study 15848611 — intervention group
Group type: EXPERIMENTAL
Intervention: CsA treatment with BB genotype
Number of subjects: 67
Study 15848611 — intervention group
Group type: EXPERIMENTAL
Intervention: bb genotype
Number of subjects: 67
Study 15848611 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy volunteers)
Number of subjects: 67
Study 12017979 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1 mg/kg vecuronium
Number of subjects: 60
Study 12017979 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.6 mg/kg rocuronium
Number of subjects: 60
Study 12017979 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.9 mg/kg rocuronium
Number of subjects: 60
Study 9460785 — intervention group
Group type: EXPERIMENTAL
Intervention: Soft contact lenses with in-air spherical aberration compensation
Number of subjects: 61
Study 9460785 — intervention group
Group type: COMPARATOR
Intervention: Standard soft contact lenses
Number of subjects: 61
Study 7605317 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief information sheet
Number of subjects: 100
Study 7605317 — intervention group
Group type: COMPARATOR
Intervention: Long information sheet
Number of subjects: 100
Study 2368894 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-controlled analgesia (PCA)
Number of subjects: 0
Study 2368894 — intervention group
Group type: COMPARATOR
Intervention: Continuous infusion of morphine
Number of subjects: 0
Study 7004742 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril 100 mg
Number of subjects: 30
Study 30922364 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative pressure wound therapy (NPWT)
Number of subjects: 0
Study 30922364 — intervention group
Group type: COMPARATOR
Intervention: Standard dressings
Number of subjects: 0
Study 28589217 — intervention group
Group type: EXPERIMENTAL
Intervention: Microperc
Number of subjects: 60
Study 28589217 — intervention group
Group type: COMPARATOR
Intervention: RIRS
Number of subjects: 60
Study 26017787 — intervention group
Group type: EXPERIMENTAL
Intervention: Birth preparation program including supervised physical exercise, relaxation exercises, and educational activities
Number of subjects: 0
Study 24096865 — intervention group
Group type: EXPERIMENTAL
Intervention: Listening training (7 sessions over 1 month)
Number of subjects: 36
Study 24096865 — intervention group
Group type: COMPARATOR
Intervention: Hearing aids without training (Control group)
Number of subjects: 36
Study 17049347 — intervention group
Group type: EXPERIMENTAL
Intervention: Two femoral neck screws with intramedullary nails
Number of subjects: 0
Study 17049347 — intervention group
Group type: COMPARATOR
Intervention: Single femoral neck screw with intramedullary nails
Number of subjects: 0
Study 15023570 — intervention group
Group type: EXPERIMENTAL
Intervention: sonepiprazole
Number of subjects: 467
Study 15023570 — intervention group
Group type: EXPERIMENTAL
Intervention: olanzapine
Number of subjects: 467
Study 15023570 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 467
Study 10919295 — intervention group
Group type: EXPERIMENTAL
Intervention: Tranexamic acid
Number of subjects: 39
Study 10919295 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study 9014063 — intervention group
Group type: EXPERIMENTAL
Intervention: 6% HES 120/0.7
Number of subjects: 48
Study 9014063 — intervention group
Group type: EXPERIMENTAL
Intervention: 6% dextran 70
Number of subjects: 48
Study 9014063 — intervention group
Group type: COMPARATOR
Intervention: Ringer's solution
Number of subjects: 48
Study 1488359 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 micrograms misoprostol (Cytotec‐Searle)
Number of subjects: 8
Study 1488359 — intervention group
Group type: COMPARATOR
Intervention: Aminophylline i.v. infusion at a rate of 500 mg/hour
Number of subjects: 8
Study 3548986 — intervention group
Group type: EXPERIMENTAL
Intervention: Diflunisal
Number of subjects: 36
Study 3548986 — intervention group
Group type: COMPARATOR
Intervention: Naproxen
Number of subjects: 36
Study 31235074 — intervention group
Group type: EXPERIMENTAL
Intervention: Tisseel (fibrin sealant) in combination with surgical anastomosis
Number of subjects: 57
Study 31235074 — intervention group
Group type: COMPARATOR
Intervention: Surgical anastomosis alone (Control)
Number of subjects: 57
Study 31002834 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral sedation with triazolam and intravenous placebo
Number of subjects: 85
Study 31002834 — intervention group
Group type: COMPARATOR
Intervention: Intravenous sedation with midazolam and oral placebo
Number of subjects: 85
Study 28153000 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac-Diabetes Transcare Intervention (in addition to usual care)
Number of subjects: 432
Study 28153000 — intervention group
Group type: COMPARATOR
Intervention: Usual Care Group
Number of subjects: 432
Study 28153000 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac-Diabetes Transcare Intervention
Number of subjects: 432
Study 25801552 — intervention group
Group type: EXPERIMENTAL
Intervention: sublingual artemether (ArTiMist) 3.0 mg/kg
Number of subjects: 91
Study 25801552 — intervention group
Group type: EXPERIMENTAL
Intervention: sublingual artemether
Number of subjects: 91
Study 23563070 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated self-management program
Number of subjects: 55
Study 23563070 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 55
Study 21864137 — intervention group
Group type: EXPERIMENTAL
Intervention: Phytoestrogen supplements with exercise
Number of subjects: 40
Study 21864137 — intervention group
Group type: COMPARATOR
Intervention: Placebo with exercise
Number of subjects: 40
Study 19675959 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavioural therapy (CBT) program
Number of subjects: 56
Study 19675959 — intervention group
Group type: COMPARATOR
Intervention: Information-only control program
Number of subjects: 56
Study 16919743 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive therapeutic alliance
Number of subjects: 753
Study 16919743 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivation
Number of subjects: 753
Study 16919743 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapists' perceptions of alliance
Number of subjects: 753
Study 16919743 — intervention group
Group type: COMPARATOR
Intervention: Treatment compliance
Number of subjects: 753
Study 15311287 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention hospitals (230 women)
Number of subjects: 656
Study 15311287 — intervention group
Group type: COMPARATOR
Intervention: Control hospitals (426 women)
Number of subjects: 656
Study 15311287 — intervention group
Group type: EXPERIMENTAL
Intervention: Physicians from intervention hospitals (72 physicians)
Number of subjects: 656
Study 15311287 — intervention group
Group type: COMPARATOR
Intervention: Physicians from control hospitals (70 physicians)
Number of subjects: 656
Study 11516922 — intervention group
Group type: EXPERIMENTAL
Intervention: Lofexidine, oxazepam, baclofen, ketoprofene, naloxone, naltrexone for 3 days
Number of subjects: 40
Study 11516922 — intervention group
Group type: COMPARATOR
Intervention: Clonidine, oxazepam, baclofen, ketoprofene, naloxone, naltrexone for 3 days
Number of subjects: 40
Study 9062473 — intervention group
Group type: EXPERIMENTAL
Intervention: recombinant human GH (rhGH) 9.5 micrograms/kg daily for 9 months
Number of subjects: 30
Study 7691256 — intervention group
Group type: EXPERIMENTAL
Intervention: rhGM-CSF (400 micrograms) for 7 days subcutaneously after chemotherapy
Number of subjects: 182
Study 7691256 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 182
Study 3741107 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate fixation of all fractures
Number of subjects: 0
Study 3741107 — intervention group
Group type: COMPARATOR
Intervention: Conservative orthopedic management (traction or plaster casts)
Number of subjects: 0
Study 29134488 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical pharmacist-assisted program (CPAP)
Number of subjects: 85
Study 26315844 — intervention group
Group type: EXPERIMENTAL
Intervention: Inpatient treatment (2 or 6 months)
Number of subjects: 51
Study 26315844 — intervention group
Group type: EXPERIMENTAL
Intervention: Ambulatory treatment
Number of subjects: 51
Study 26315844 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 51
Study 24487732 — intervention group
Group type: EXPERIMENTAL
Intervention: Desflurane at 0.3 MAC
Number of subjects: 14
Study 24487732 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane at 0.3 MAC
Number of subjects: 14
Study 24487732 — intervention group
Group type: EXPERIMENTAL
Intervention: Desflurane at 0.5 MAC
Number of subjects: 14
Study 24487732 — intervention group
Group type: EXPERIMENTAL
Intervention: Desflurane at 0.7 MAC
Number of subjects: 14
Study 24487732 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane at 0.5 MAC
Number of subjects: 14
Study 24487732 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane at 0.7 MAC
Number of subjects: 14
Study 23011560 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mg oral gabapentin
Number of subjects: 126
Study 23011560 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 mg oral gabapentin
Number of subjects: 126
Study 23011560 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 126
Study 20556208 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily use of long-acting beta2-agonist (LABA) for 12 weeks with conventional reversibility test (2 puffs terbutaline)
Number of subjects: 28
Study 20556208 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily use of long-acting beta2-agonist (LABA) for 12 weeks with reversibility test using refracted doses (1 puff every 5 min, total 4 puffs)
Number of subjects: 28
Study 18652709 — intervention group
Group type: EXPERIMENTAL
Intervention: Penile block using 0.25 mL kg(‐1) 0.5% bupivacaine (Group P)
Number of subjects: 40